Clinical trial No longer in our active list Phase 2 Interventional Ages 18 and up

Testing darolutamide for salivary gland cancers driven by testosterone

Official title: A Phase 2 Study of Darolutamide in Combination With Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer

Run by National Cancer Institute (NCI) · NCT05669664 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing if a new combination of medications can help people with certain types of salivary gland cancers that are hard to treat.

Research outlook What's coming for Salivary gland cancer: the next 6 months to 5 years

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment21 (estimated)
SponsorNational Cancer Institute (NCI)
NIH
Locations27 sites (Irvine, California and 26 other locations)
Trial IDNCT05669664 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with confirmed androgen receptor positive salivary gland cancer that is recurrent, metastatic, or unresectable.

Probably not a fit

Patients who have previously received androgen receptor-targeted therapy or those with a performance status greater than 2 may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial evaluates the effectiveness of darolutamide, an androgen receptor inhibitor, in combination with leuprolide acetate, a gonadotropin-releasing hormone agonist, for treating patients with androgen receptor positive salivary gland cancers that are recurrent, metastatic, or unresectable. The study aims to assess the best overall response rate, progression-free survival, and overall survival of participants over one year. Patients will receive darolutamide orally and leuprolide acetate via injection, with regular monitoring through biopsies and imaging. The trial also explores molecular and genomic biomarkers to understand treatment responses better.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with aggressive salivary gland cancers that currently have limited treatment options.

How similar studies have gone: While this approach is novel for salivary gland cancers, similar strategies using androgen receptor inhibitors have shown promise in other cancer types.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients must have histologically or cytologically confirmed salivary gland cancer that is recurrent/metastatic or unresectable/locally advanced, with AR expression detected by immunohistochemistry (IHC) on a Clinical Laboratory Improvement Act (CLIA)-approved assay. Androgen receptor testing by immunohistochemistry (IHC) can be performed locally in a CLIA (Clinical Laboratory Improvement Amendments) certified lab
* Patients must have measurable disease
* Patients must have not had prior AR-targeted therapy, except for AR-targeted therapy administered in the neoadjuvant and/or adjuvant setting and with disease recurrence more than 6 months since treatment completion
* Age \>= 18 years. Because no dosing or adverse event data are currently available on the use of darolutamide in combination with leuprolide acetate in patients \< 18 years of age, children are excluded from this study
* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%)
* Absolute neutrophil count \>= 1,000/mcL
* Platelets \>= 100,000/mcL
* Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) (exception: patients with elevated bilirubin due to Gilbert's disease would be eligible for the trial)
* Aspartate aminotransferase (AST) (serum (glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase (\[SGPT\]) =\< 3 x institutional ULN
* Creatinine =\< 1.5 x institutional ULN
* Glomerular filtration rate (GFR) \>= 30 mL/min/1.73 m\^2 (by Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\])
* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
* Patients with treated brain metastases are eligible
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
* The effects of darolutamide on the developing human fetus are unknown. For this reason and because androgen receptor inhibitor agents as well as other therapeutic agents used in this trial are known to be teratogenic (leuprolide-acetate), women of child-bearing potential and men must agree to use adequate contraception (non-hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men and women treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 7 days after completion of darolutamide administration or after the depot interval for the leuprolide-acetate dose used has been completed, whichever is longer
* Ability to understand and the willingness to sign a written informed consent document
* Patients must have tumors that are safely accessible for biopsy.

  * Note: Two research biopsies are mandated in this trial. If the biopsy is deemed to be unsafe after attempting the first biopsy, the patient will remain eligible for the trial and subsequent tumor biopsies will not be required

Exclusion Criteria:

* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the exception of alopecia and peripheral neuropathy
* Patients with a vascular or ischemic event within 6 months of study registration
* Patients who are receiving any other investigational agents
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to darolutamide or leuprolide acetate
* Patients on combined P-gp and strong or moderate CYP3A inducers or BCRP substrates are excluded. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
* Patients with uncontrolled intercurrent illness
* Pregnant women are excluded from this study because darolutamide is an androgen receptor inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with darolutamide and leuprolide-acetate, breastfeeding should be discontinued if the mother is treated with darolutamide and leuprolide-acetate. These potential risks may also apply to other agents used in this study.
* Patients with moderate hepatic impairment (Child-Pugh Class B or C)

Where it's running

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
    Irvine, California, United States
    Recruiting
  • Los Angeles General Medical Center
    Los Angeles, California, United States
    Recruiting
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California, United States
    Recruiting
  • UC Irvine Health/Chao Family Comprehensive Cancer Center
    Orange, California, United States
    Recruiting
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California, United States
    Recruiting
  • UCHealth University of Colorado Hospital
    Aurora, Colorado, United States
    Recruiting
Show 21 more locations
  • Emory University Hospital Midtown
    Atlanta, Georgia, United States
    Recruiting
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois, United States
    Recruiting
  • UC Comprehensive Cancer Center at Silver Cross
    New Lenox, Illinois, United States
    Recruiting
  • University of Chicago Medicine-Orland Park
    Orland Park, Illinois, United States
    Recruiting
  • UChicago Medicine Northwest Indiana
    Crown Point, Indiana, United States
    Recruiting
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey, United States
    Recruiting
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey, United States
    Recruiting
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey, United States
    Recruiting
  • Memorial Sloan Kettering Commack
    Commack, New York, United States
    Recruiting
  • Memorial Sloan Kettering Westchester
    Harrison, New York, United States
    Recruiting
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    New York, New York, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York, United States
    Recruiting
  • Memorial Sloan Kettering Nassau
    Uniondale, New York, United States
    Recruiting
  • UNC Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina, United States
    Recruiting
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma, United States
    Recruiting
  • University of Pittsburgh Cancer Institute (UPCI)
    Pittsburgh, Pennsylvania, United States
    Recruiting
  • Huntsman Cancer Institute/University of Utah
    Salt Lake City, Utah, United States
    Recruiting
  • University of Virginia Cancer Center
    Charlottesville, Virginia, United States
    Recruiting
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
    Madison, Wisconsin, United States
    Recruiting
  • University of Wisconsin Carbone Cancer Center - University Hospital
    Madison, Wisconsin, United States
    Recruiting
  • M D Anderson Cancer Center
    Houston, Texas, United States
    Suspended

Study contacts

  • Principal investigator: Alan L Ho — JHU Sidney Kimmel Comprehensive Cancer Center LAO

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Comparing treatments for advanced HER2-positive salivary gland cancer

    This study is testing if a new drug called T-DM1 works better than the usual treatment for people with advanced HER2-positive salivary gland cancer, while also looking at another drug for those with lower levels of HER2.

    Recruiting at 143 sites Phase 2 NRG Oncology · Birmingham, Alabama and 153 other locations · NCT05408845

  • Registry for postoperative radiochemotherapy in salivary gland cancer

    This study is testing a new combined treatment of radiation and chemotherapy after surgery for people with advanced salivary gland cancer to see how well it works and how patients tolerate it.

    Recruiting University of Erlangen-Nürnberg Medical School · Erlangen · NCT06464198

  • Evaluating Ivonescimab for advanced salivary gland cancers

    This study is testing a new treatment called Ivonescimab to see if it can help people with advanced salivary gland cancers feel better and improve their health.

    Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06805617

  • Multi-omics analysis of progression and tumor biology in head and neck adenoid cystic carcinoma

    We will test whether different tumor biology types in people with metastatic head and neck adenoid cystic carcinoma explain why some cancers grow slowly while others grow faster.

    Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07507578

  • Implantable microdevice drug screening for salivary and head and neck cancers

    This will test whether a tiny implantable microdevice can safely and quickly deliver and screen multiple cancer drugs inside salivary gland and other head and neck tumors in patients scheduled for surgical removal.

    Recruiting at 2 sites Early Phase 1 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT05553782

  • Abiraterone with dalpiciclib in AR-positive, HER-2 negative salivary gland cancer

    This phase 2 trial tests whether combining abiraterone and dalpiciclib helps people with AR-positive, HER-2 negative salivary gland cancer that has come back or spread.

    Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07815522

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.